Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘Visiongain’

‘Cancer Drug Market Will Reach $75 Billion in 2012’ visiongain Report Predicts

Posted by fidest press agency su martedì, 28 febbraio 2012

London (PRNewswire) A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. Visiongain is a business information provider based in London, UK.The new study predicts that overall revenues for anti-cancer treatments will increase strongly from 2012 to 2022. Individual drugs will benefit too. Roche will continue to be the leading company in the cancer-treating drugs market throughout the study’s forecast period. Through emerging technologies and increasing demand in developed and developing countries, the future of cancer treatments holds great promise. That revenue growth will be mainly owing to the worldwide increase in cancer incidence and prevalence. New opportunities for cancer treatment exist, with high sales likely from many drugs – small-molecule products and biological agents (biologicals) – to 2022. Also, R&D pipelines in oncology are strong, including those for monoclonal antibodies (MAbs).The visiongain pharmaceutical industry analyst at visiongain, said, “Although oncology is one of the most researched areas of medicine, there remain un-met and under-met treatment needs. There is a need for well targeted therapies with better safety and efficacy. It is crucial that anti-cancer drugs have minimal side effects, so that the quality of patients’ lives can be enhanced. Pharma companies will further explore this field, making therapeutic progress this decade. In particular, companion diagnostic tests with drugs will help in cancer treatment, giving more-personalised, better-targeted medicine.”

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

‘BD to Dominate the Pre-filled Syringes Market to 2022’ Visiongain Report Predicts

Posted by fidest press agency su venerdì, 17 febbraio 2012

London, (PRNewswire)A new report by visiongain predicts that Becton, Dickinson & Co (BD) will be the largest player in the pre-filled syringe market through to 2022. In 2012, that company’s pre-filled syringe and related technology revenue will reach $1.14 billion, having grown with a CAGR of 7.0% since 2010. In the same period, the pre-filled syringe market will grow with a CAGR of 8.5%. These sales forecasts appear in Top Pre-Filled Syringe Manufacturers: Market Outlook 2012-2022, published in February 2012. Visiongain is a business information provider based in London, UK. This new study profiles and analyses leading companies manufacturing and supplying pre-filled syringes to drug manufacturers. Visiongain estimates that in 2011 five companies accounted for the supply of more than 90% of glass pre-filled syringes to the pharmaceutical industry. As well as BD, leading companies in the market include Gerresheimer, Schott, MGlas and Nuova Ompi. A worldwide presence and the production of both glass and plastic pre-filled syringes mean that BD, Gerresheimer and Schott are the market leaders in 2012. Those companies have diversified product portfolios, appealing to a broad range of customers. Over the coming 10 years, those suppliers will benefit from increased demand for plastic syringes from pharma companies. This will be driven by the development of new biologics, vaccines and biosimilars, products stimulating the demand for stable, convenient injection systems for complex, sensitive medicines. Richard Lang, a pharmaceutical industry analyst at visiongain, said: “The leading companies in the market at present can expect to retain their position over the coming decade. However, to gain market share they must follow a number of key market trends, including the increasing development of biologics and biosimilars and greater demands for safety in syringe products.” Visiongain’s report also analyses the performance of leading manufacturers of pen injectors, autoinjectors and pre-filled syringe components. In 2010, autoinjectors and pen injectors accounted for 24.0% of the pre-filled syringe market. Leading suppliers of autoinjectors include Ypsomed, Owen Mumford, SHL Group and BD. The rising incidence of diabetes, as well as other chronic diseases, worldwide and the increased demand for drugs that can be administered in the home healthcare setting will stimulate demand for pre-filled drug dispensing products over the coming 10 years. Syringe manufacturers must ensure that new products meet the demands of patients, healthcare professionals and drug developers. Expansion of the pre-filled syringe industry and market also offers opportunities to medical device component manufacturers, especially companies making plungers, needle shields and tip caps. The three leading companies in that sector, Datwyler, West and Stelmi, control significant market share as a result of partnerships with leading drug and syringe manufacturers. Top Pre-Filled Syringe Manufacturers: Market Outlook 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »